ArticleTranslational cancer research2026
Establishment of a model to predict the recurrence time of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For hormonal receptor-positive (HR Methods: In this study, the female patients with HR Results: A total of 639 patients treated in the hospital between April 2007 and October 2019 were included. Median age of these patients at the initial diagnosis of primary tumors was 47 years old. Among them, 382 patients (59.8%) were presented with early recurrence (DFS ≤5 years), and 257 patients (40.2%) were presented with late recurrence (DFS >5 years). The median DFS was 50.0 months. Both univariate and multivariate analyses showed that a higher level of Ki-67 (P=0.005, 0.003) and more positive lymph nodes (P=0.003, 0.021) were associated with shorter DFS. A nomogram based on potentially associated clinicopathological factors was constructed and validation results showed that the nomogram was well-calibrated to predict the recurrence time of these patients (AUC =0.703, C-index =0.697). Conclusions: A well-calibrated nomogram is constructed using the data of clinicopathological factors obtained from 639 HR
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.